Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Recruiting in Palo Alto (17 mi)
Overseen byAadel Chaudhuri, M.D., Ph.D.
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Washington University School of Medicine
No Placebo Group
Trial Summary
What is the purpose of this trial?Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Eligibility Criteria
Inclusion Criteria
Eligible healthy donors will be at least 18 years of age.
Participant Groups
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Washington University School of MedicineSaint Louis, MO
Loading ...
Who Is Running the Clinical Trial?
Washington University School of MedicineLead Sponsor
National Center for Advancing Translational Science (NCATS)Collaborator
Roche Sequencing SolutionsIndustry Sponsor
The V Foundation for Cancer ResearchCollaborator
National Institute of General Medical Sciences (NIGMS)Collaborator
Radiological Society of North AmericaCollaborator
National Center for Advancing Translational Sciences (NCATS)Collaborator
The Foundation for Barnes-Jewish HospitalCollaborator
SkandalarisCollaborator